AlphaLiquid 100
118-gene blood-based targeted comprehensive genomic profiling assay for solid tumors.
- Developer
- IMBdx
- Intended use
- Monitoring, Other
- Cancer scope
- Solid tumors
- Specimen
- Peripheral whole blood
- Molecular modality
- Copy number, DNA mutation
- Current version
- Current 118-gene, 466-kb targeted hybrid-capture AlphaLiquid 100 configuration with SNV/indel/CNA/fusion/HRR and MSI/TMB reporting
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.